MedTrace Logo

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

NCT00624741 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2012-06-22

No results posted yet for this study

Summary

This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.

Conditions

  • Parkinson Disease

Interventions

DRUG

Pergolide

Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624741 on ClinicalTrials.gov